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Abstract
Antenatal corticosteroid treatment (ACT) has been widelyBackground: 
accepted as a safe, beneficial treatment which improves outcomes
following preterm birth. It has been shown to reduce respiratory distress
syndrome and neonatal mortality and is commonly used in threatened or
planned preterm delivery, as well as prior to elective Caesarean-section at
term. There are some concerns however, that in some cases, ACT is used
in patients where clinical benefit has not been established, or may
potentially increase harm. Many women who receive ACT do not deliver
preterm and the long-term consequences of ACT treatment are unclear.
This study aims to evaluate the benefits and harms of ACT using latest trial
evidence to allow refinement of current practice.
This study will compare ACT with placebo or non-treatment.Methods: 
Inclusion criteria are: Randomised Controlled Trials (RCT) comparing ACT
vs. no ACT (with or without placebo) in all settings. Exclusion criteria are:
non-randomised or quasi-randomised studies and studies comparing single
vs. multiple courses of ACT. Main outcomes are to evaluate, for women at
risk of preterm birth or undergoing planned Caesarean- section, the
benefits and harms of ACT, on maternal, fetal, newborn, and long-term
offspring health outcomes.
The individual participant data (IPD) of identified RCTs will be collected and
consecutively synthesised using meta-analysis with both a one-stage
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 consecutively synthesised using meta-analysis with both a one-stage
model where all IPD is analysed together and a two-stage model where
treatment effect estimates are calculated for each trial individually first and
thereafter pooled in a meta-analysis. Sub-group analysis will be performed
to identify heterogeneous effects of ACT across predefined risk groups.
Co-opt is the Consortium for the Study of PregnancyDiscussion: 
Treatments and aims to complete a robust evaluation of the benefits and
harms of ACT. This IPD meta-analysis will contribute to this by allowing
detailed interrogation of existing trial datasets.
 (03/02/2020)PROSPERO registration: CRD42020167312
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Plain language summary
When babies are born prematurely, respiratory problems are 
the most common cause of illness and death and the most 
common reason for admission to the special care baby unit or 
neonatal intensive care. Babies born by planned Caesarean- 
section are also at greater risk of respiratory problems than 
those bornby vaginal delivery.
Antenatal corticosteroid treatment (ACT) has long been used 
to help reduce respiratory problems and neonatal death and 
is a cornerstone of treatment when preterm birth (defined as 
birth at <37 weeks gestation1) is planned or expected, or when 
Caesarean-section at any gestation, is planned. Corticosteroids 
are produced naturally by the mother when she goes into labour. 
Giving corticosteroids to the mother if she is at risk of giving 
birth prematurely, aims to augment this natural response. 
Giving ACT to the mother helps the lungs of the fetus to 
mature more quickly, toenable them to function better after 
birth.
Although ACT has been used widely for a number of years, the 
evidence of benefit from randomised controlled trials is based 
mainly on those who receive ACT at 26-34 weeks of preg-
nancy. While there are observational data showing benefit at 
other gestational ages, there is some concern that the benefit 
may not be as great as previously estimated, particularly in later 
gestation, and there may even be risk of harm. The evidence 
suggests greatest benefit from ACT is derived if they are given 
between 24 hours and 7 days before delivery, however timing 
of preterm birth is very difficult to predict. This means many 
women are being given ACT but then do not give birth within 
7 days. In these women it is uncertain whether potential benefit 
outweighs the potential harms of ACT.
The risk profile of ACT is not fully understood. It is known 
that the short term risks of ACT include increased rates of 
neonatal hypoglycaemia (low blood sugar), which if not 
recognised and treated appropriately is an independent risk 
factor for developmental delay2–5. There is a lack of evidence 
assessing the long-term risks. However there is concern that 
being exposed to ACT as a fetus could increase risk of 
conditions such as cardiovascular disease and diabetes mellitus 
later in life2. With these risks in mind, it is important to fully 
establish the risk benefit profile for all babies, and their 
mothers, receiving ACT.
This study will collate data from previous trials with the aim 
of gaining greater understanding of the potential benefits and 
harms of ACT in mothers and in babies born at all gestations 
and by all modes of delivery, and also in those who receive 
ACT but do not deliver within 7 days. The results will be used 
to inform clinical guidelines on ACT use and allow clinicians to 
follow best evidence-based practice.
Introduction
Description of the condition
Preterm birth is the leading cause of death in newborns, and is 
responsible for 35% of neonatal mortality6. Respiratory distress 
syndrome (RDS) is one of the main causes of early neonatal 
mortality and morbidity in premature neonates. It affects one 
third of babies born before 32 weeks and is caused primarily 
by a combination of immature lung development, surfactant 
deficiency and immaturity in other organ systems7. 
Description of the intervention
ACT mimics the natural surge of endogenous corticosteroids 
which occurs around term in women who labour, and works by 
thinning alveolar walls to increasing lung surface area for gas 
exchange3. It also causes increased transcription of surfactant 
by type II pneumocytes which increases tissue compliance and 
lowers surface tension3,8. It was first evaluated in humans in 
Liggins’ seminal randomised-controlled trial (RCT) in 19729, 
and this evidence was consolidated by a systematic review in 
199010. Since then the usage of ACT has increased worldwide. 
In the USA, between 1991-1999, ACT use increased from 
24%–72% in preterm births, and in California a cross-sectional 
analysis of 33,610 low birth weight babies between 2005–2011, 
usage was as high as 92.9%11 
ACT has been shown to confer significant morbidity and mor-
tality benefit for both preterm neonates, and neonates born by 
elective Caesarean section who do not receive the same physi-
ological endogenous surge3. It reduces RDS rates overall, as 
well as reducing moderate and severe RDS and need for respira-
tory support for all neonates3. For preterm neonates it also has a 
vasoconstrictive effect on the cerebral blood flow, thereby reduc-
ing rates of intraventricular haemorrhage3,7. ACT also reduces 
necrotising enterocolitis (NEC) and rates of retinopathy of 
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prematurity, as well as early systemic infection and requirement 
for neonatal intensive care unit (NICU) admission7,12. 
ACT is widely used and widely accepted as a safe and 
beneficial treatment for preterm labour, planned preterm birth 
and elective Caesarean-section. It is given when preterm 
labour is predicted or a preterm Caesarean-section is planned, 
to improve fetal lung maturation, and confer other morbidity 
and mortality benefits2,7,13. ACT (specifically dexamethasone 
phosphate) has been listed on the WHO Model List of 
Essential Medicines14 as well as being identified as one of the 
UN 13 life-saving commodities for mother and child15,16. 
There is however, a lack of evidence of the long-term 
consequences of ACT. There is concern that excess exposure 
to ACT as a fetus may alter Hypothalamic-Pituitary-Adrenal 
(HPA) axis programming and predispose to increased risk 
of metabolic disease with dyslipidaemia, impaired glucose 
metabolism and hypertension, in addition to behavioural changes 
such as attention deficit, increased aggression or elevated stress 
response2,17. 
Trial data on long-term consequences is limited, although one 
30 year follow up of trial data found no significant difference in 
body size, blood lipids, blood pressure, plasma cortisol or car-
diovascular disease between the group who had received ACT 
and the control group, although they did find increased fasting 
insulin which is an early marker of insulin resistance18. From 
observational studies, data collected on body size, blood pres-
sure and behavioural assessment from children who had received 
ACT at two year follow up found no significant differences in 
anthropometric or neurocognitive measures19,20. There is however 
clear evidence from animal data that exposure to glucocorticoid 
excess during pregnancy predisposes to adverse metabolic 
outcomes in adult life17,21. 
Current evidence and knowledge
There have been three recent Cochrane reviews evaluating the 
use of ACT vs. placebo for preterm birth in different circum-
stances7,22,23. The largest: “Antenatal corticosteroids for accelerating 
fetal lung maturation for women at risk of preterm birth”, 
updated by Roberts et al. in 2017, comprises 30 RCTs including 
7774 women and 8158 infants assessing the use of ACT in 
acceleration of fetal lung maturation among women with 
imminent preterm delivery7. The review authors concluded 
ACT is associated with a reduction in a number of adverse 
outcomes related to prematurity including perinatal death, 
neonatal death and moderate/severe RDS7. A separate review 
in 2018 evaluated ACT use compared to placebo in Caesarean- 
section at term: “Corticosteroids for preventing neonatal respira-
tory morbidity after elective Caesarean-section at term”. This 
review included 4 trials with a total of 3956 women and 3893 
live infants and again found a reduction in all RDS (Risk ratio 
(RR) 0.48 95% Confidence Interval (CI) 0.27-0.84)22. A 2015 
Cochrane review “Repeat doses of prenatal corticosteroids for 
women at risk of preterm birth” assessed the risks and benefits 
of repeat courses of ACT if birth does not occur within 7 days of 
first dose23. This included 10 trials with 4733 women and 5700 
infants who had received one course of ACT, and compared those 
who had further courses, with those who had no further treatment. 
Short term benefits were seen with reduction in RDS (RR 0.83, 
95% CI 0.75-0.91) in women who had multiple courses, and there 
was no increase in adverse outcomes seen with repeat courses23. 
Subsequent to this, an IPD meta-analysis has been completed 
evaluating repeat courses and identified 11 trials24. They too 
found reduction in need for respiratory support (RR0.91, 95% 
CI 0.85-0.97) and no significant difference in serious outcome 
(RR 0.92, 95% CI 0.82-1.04)24. A systematic literature evalu-
ating six clinical trials which included 5698 women receiving 
steroids at greater than 34 weeks gestation, found that in 
this group RDS was significantly reduced (RR 0.74; 95% CI 
0.61-0.91). Neonatal care requirements were also reduced with 
less mechanical ventilation, surfactant administration and NICU 
admission25. 
Recently, the Antenatal Corticosteroids Trial triggered significant 
concerns into current ACT usage. It was a large, multi-centre, 
cluster-randomised trial published in 2015 by Althabe et al., 
designed as a implementation trial evaluating a package of inter-
ventions to increase the use of ACT in 6 LMICs for women at 
risk of PTB. The trial included data from 51 intervention clus-
ters including 48219 women and 48698 births and 50 control 
clusters including 51523 women and 52007 births. Although 
the study was successful in increasing ACT uptake, there was 
minimal evidence of benefit in small infants (<5th birthweight 
percentile), evidence of harm in larger infants (>25th birthweight 
centile), and increase in maternal infection rates26,27. These 
findings weresurprising and led to further evaluation of the 
existing evidence
ACT use in specific patient groups
ACT given >34 weeks gestation. In the Roberts et al. review7 
there was a post-hoc sub-group analysis of ACT use among 
women greater than 34 weeks gestation. In this subgroup they 
found ACT did reduce RDS (RR 0.65; 95% CI 0.58-0.73) but 
there was no significant reduction in perinatal mortality (RR 
1.03; 95% CI 0.29-3.67)7. The Antenatal Late Preterm Ster-
oids (ALPS) trial contributed much of these data, and did also 
find that ACT use was associated with increased rates of neona-
tal hypoglycaemia in the treatment group (RR 1.60; 95% CI, 
1.37 to 1.87)5. 
ACT given prior to planned Caesarean-section. Neonates deliv-
ered by Caesarean section are known to have higher rates of res-
piratory morbidity than those born vaginally, and these rates 
are higher still in planned Caesarean-section before the onset 
of labour21,22,28. Although some of this increase is due to the 
indication for Caesarean-section, the RDS in these neonates 
may have a different pathophysiology to that in prematurity and 
the lack of the physiological corticosteroid surge which occurs 
during labour is a contributing factor22. As discussed above, 
the Cochrane review found a 52% reduction in RDS following 
planned Caesarean-section when ACT was given 48 hours 
before22. However, there was considerable risk of bias in the 
evidence as three of the four studies included were unblinded. In 
addition, there was no significant change in mortality, (RR 
0.67, 95% CI 0.11-4.10). Given that in high income settings 
there are now facilities to manage neonatal RDS, if ACT has 
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long-term health implications risks may outweigh the benefits in 
this sub-group21,29. 
Time from ACT to delivery >7 days. The cellular changes caused 
by ACT are acute and transitory, and there is some evidence that 
ACT is beneficial when given 24 hours to 7 days before delivery, 
but that after 7 days there is no benefit3,30. However, even 
when threatened preterm labour is established, it is not possible to 
accurately estimate exactly when delivery will occur. It has been 
reported that up to a quarter of women who were given ACT did 
not deliver within 7 days3,31. There is limited data on ACT use 
in this sub-group and we are unsure of the benefits and possible 
harms for these women.
If after 7 days of ACT administration, birth has not occurred 
(but is still considered imminent) current guidelines recommend 
repeating ACT32. The Cochrane review evaluating repeat doses of 
ACT found a reduction in RDS (RR 0.83, 95% CI 0.75-0.91) 
and serious infant outcome (RR 0.84, 95% CI 0.75-0.94) 
following a repeat course of ACT23. There was no evidence at 
childhood follow-up (24 months) of any statistically significant 
differences in rates of neurodisability (including cerebral 
palsy and cognitive impairment) (RR 1.03, 95% CI 0.71-1.50). 
Further long-term follow up however is required to evaluate the 
long-term benefits and risks for both women and babies24. 
ACT given to those who deliver at term. It is difficult to accurately 
predict when birth will occur after threatened preterm labour33. 
The ORACLE collaborative group conducted a trial of treat-
ment of 4826 women with Preterm Prelabour Rupture of Mem-
branes (PPROM) and found 80% of women “diagnosed” with 
preterm labour actually delivered after 37 weeks34. While there 
is evidence that ACT given to women at greater than 37 weeks’ 
gestation in the context of elective Caesarean-section reduces 
incidence of RDS and thereby reduces neonatal care require-
ments25, this short term benefit may not be worthwhile 
in the context of possible long-term risk.
How the intervention might work
In late gestation and during labour, there is a surge of 
endogenous corticosteroids3, and ACT administration aims to 
imitate this. This surge is important in the development of 
multiple organ systems and supports the transition from the 
intra- to extra-uterine environment. In the lungs, corticosteroids 
stimulate the transcription of surface proteins involved in 
surfactant production, and also play a key part in alveolar 
fluid clearance post-delivery3,35. In addition, corticosteroids act 
systemically in both the mother and the fetus, affecting the 
brain, heart, kidneys, hypothalamus and circulation3. 
Why it is important to do this review
With the clear evidence of short-term benefit of ACT, particu-
larly in preterm babies, few may question the rationale for con-
tinued usage. However the lack of evidence on long term effects 
of ACT, particularly among those receive ACT but are not born 
preterm, mean there are further questions to be answered. By per-
forming an IPD analysis we will be able to look at all published 
trial data on ACT and perform more detailed sub-group analysis 
with the aim of answering questions on those who receive ACT 
but do not deliver within 7 days, those who receive ACT but 
deliver at term, and also the differential benefits of ACT at dif-
ferent gestational ages. This study will be complemented by an 
IPD analysis using observational data, evaluating the same out-
comes, as well as giving the opportunity to evaluate long-term 
outcomes from cohort data (PROSPERO CRD42019137260).
Out of the 30 studies included in the Roberts et al. review, 
14 were published prior to 19907. Neonatal care has seen 
significant advances during that time- notably the use of con-
tinuous positive airways pressure (CPAP), and the availability 
of surfactant therapy. It may be that when compared with 
current standard neonatal care within a high income setting, 
ACT no longer produces such significant reductions in 
mortality and morbidity2,21. In the USA there were significant 
reductions in infant mortality from RDS prior to the widespread 
introduction of ACT4. With this in mind, it is possible that 
current ACT practice may be conferring insufficient benefit to 
the neonate to justify the exposure to unquantified long-term 
risks of metabolic disease and neurocognitive alteration2,17,21 By 
performing subgroup analysis of year of birth on IPD, we will 
be able to glean greater understanding about the absolute impact 
of ACT in the context of current neonatal care. In addition, from 
our initial scoping searched, since the Roberts et al. Cochrane 
review, there have been four new ACT RCTs published36–39, as  
well as an additional four studies currently in progress. This 
means that in addition to the detailed sub-group analysis we will 
be able to perform with the IPD approach, we will also have 
a body of new data to add to the picture.
In addition, there was considerable variability in the inclu-
sion of women with high-risk conditions such as preterm prela-
bour rupture of membranes (PPROM). Using aggregate data it is 
hard to evaluate the differential effects on these women whereas 
IPD analysis will allow a more nuanced approach to identifying 
individual women with specific high-risk conditions40.
This study aims to aims to answer some of the outstanding ques-
tions around the risks and benefits of ACT use, by using an IPD 
approach. It has a number of benefits such as the ability to qual-
ity assess data in greater detail and to standardise outcomes 
and statistical methods across studies40. It will also allow more 
detailed sub-group analysis to enable exploration of the effects 
of ACT among specific patient groups, such as in multiple preg-
nancies, or in maternal infection. This is difficult to do with 
aggregate data and we will be able to provide a more nuanced 
analysis. We are also able to account for the impact of other inter-
ventions, such as tocolysis41,42. IPD is also able to produce more 
clinically relevant results than aggregate data analysis alone, 
as it enables more powerful assessment of treatment effects40. 
The current ACT usage is a “one-size fits all” approach and the 
ambition of the IPD meta-analysis is to breakdown the appro-
priateness of this with greater granularity than an aggregate 
data approach allows.
Aims
The aims of this study are to undertake a robust evaluation 
of the benefits and harms of ACT given to women at risk of 
preterm birth. We aim to ascertain, with greater specificity than 
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previous meta-analyses, the impact of ACT use at different ges-
tational ages. We also aim to evaluate with greater specificity 
what the effective dose is, and the effective time window between 
administration and subsequent delivery. This evaluation will help 
refine the criteria for ACT administration to maximise benefits 
and avoid potentially harmful side effects.
Objectives
Primary objective. To evaluate, for women at risk of pre-
term birth or undergoing planned Caesarean-section, the ben-
efits and harms of ACT compared to placebo or no treatment, 
on maternal, fetal, newborn, and long-term offspring health 
outcomes.
Methods and design
Protocol development and registration
This protocol has been registered with PROSPERO 
(CRD42020167312) on 3 February 2020, and has been devel-
oped in accordance with the Preferred Reporting Items for 
Systematic review and Meta-analysis Protocols (PRISMA-P) 
checklist (please see reporting guidelines)43. 
Inclusion and exclusion criteria
Inclusion criteria: RCTs comparing ACT vs. no ACT (with or 
without placebo) in all settings.
Exclusion criteria: non-randomised or quasi randomised studies. 
Women and infants participating in studies looking at single vs 
multiple courses of ACT.
Population
Women with singleton or multiple pregnancy at any gestation, 
who receive ACT as part of a RCT trialling ACT for preterm 
labour or elective Caesarean-section at any gestation.
Intervention
Antenatal administration of any exogenous corticosteroid com-
monly used for fetal lung maturation given by IM injection (betame-
thasone or dexamethasone). Any dosing regimen will be accepted.
Comparators
The comparator trial arm- women at risk of preterm birth 
or prior to elective Caesarean-section at any gestation who 
receive either placebo, or no treatment.
Study design
RCTs will be included. Non-randomised or quasi-randomised trials 
will be excluded to minimise bias. Where IPD cannot be obtained, 
aggregate data from the study will be included. Sensitivity 
analysis will be performed to account any impact of this.
Trial identification
Initial literature searches and screening have been carried out as 
part of the development of this protocol. Roberts 2017 Cochrane 
review of all RCTs evaluating ACT use7 was used as a baseline 
and the Cochrane Pregnancy and Childbirth search strategy was 
used as the basis of our strategy and re-run to include papers 
published since their search completed in June 2017. Data-
bases searched (as per the Cochrane strategy) were MEDLINE, 
Embase, CINAHL and Cochrane. Search strategies are provided 
as extended data44. In addition to this, the trial registers (Clini-
calTrials.gov, ISCTRN and the WHO ICTRP portal) were also 
searched in order to identify any relevant ongoing trials, and any 
unpublished trials where data collection had been completed were 
eligible for inclusion. Reference lists of review papers and 
other relevant studies were also screened for relevant papers.
All titles and abstracts identified by the search will be screened 
independently by two reviewers to identify full papers. If no 
full paper is available, authors will be contacted. Any discrep-
ancies in screening will be resolved by discussion with a senior 
group member.
Details of the screening including reasons for inclusion and 
exclusion will provided as a PRISMA diagram.
Data provision and coding
Trial investigators will be asked to submit data in a standard-
ised, anonymised format using standardised coding developed 
for this project. If this is not possible, anonymised data will be 
accepted in any reasonable format and re-coded by the research 
team.
Data will be requested for all women randomised for the 
trial, including any who were excluded from the trial analysis.
All patient identifiable information including identifying num-
bers will be removed and replaced by a sequential numbering 
system which will be kept securely by the research group.
A list of data items to be requested can be found in the extended 
data44.
Data storage and confidentiality
A data management plan will be developed prior to receipt of 
the data. All IPD will be received via secure online transfer or 
encrypted email. It will be stored securely on the University of 
Edinburgh server. Data will be accessible only to those working 
directly on the project. No data will be copied to personal devices 
such as memory sticks or laptops.
Critical appraisal, data checking and quality assurance
The data will be critically appraised based on the trial proto-
cols, the publications and on checking of the IPD. Risk of bias 
will be assessed using the Cochrane Revised risk-of-bias tool 
(ROB2)45. At least two researchers will undertake quality assess-
ment of data with any discrepancies to be resolved by a senior 
member of the group.
All IPD data will be checked on receipt for consistency and integ-
rity of randomisation. Data will be compared with the trial pub-
lication for any inconsistencies. Again this will be done by two 
independent researchers. In case of inconsistencies, the principal 
investigator of the trial will be contacted.
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If any datasets are deemed to be insufficient quality (based on 
a “High” ROB2 score), they will be excluded from the analy-
sis. This will be done either for the dataset as a whole, or 
from particular analyses, depending on the data problem.
Data description
A descriptive table along with a narrative summary will be 
produced outlining the key design features and demographic 
characteristics of each dataset included. Excluded datasets 
will be listed along with reasons for exclusion.
Main outcomes
Primary fetal/neonatal outcomes. Extended perinatal mortality 
(defined as stillbirth or death within first 28 days of life46)
Primary maternal outcome. Maternal infection up to 6 weeks 
after trial entry (chorioamnionitis, pyrexia requiring antibiotics, 
puerperal sepsis, intrapartum fever requiring antibiotics or 
postnatal pyrexia requiring antibiotics)
Primary long-term outcomes for offspring. Neurodevelopmen-
tal disability at follow-up (blindness, deafness, moderate/severe 
cerebral palsy (however defined by study authors), or develop-
ment delay/intellectual impairment (defined as developmental 
quotient or intelligence quotient less than -2 standard devia-
tion below population mean), or cerebral palsy (abnormal tone 
with motor dysfunction)).
Adverse cardiometabolic outcomes at follow up (lipid dys-
regulation, high blood pressure (as defined by NICE CKS)47, 
impaired glucose tolerance (based on oral glucose tolerance 
test), presence of type 2 diabetes (based on fasting glucose or 
glucose tolerance test).
Secondary outcomes
The following additional outcomes will be explored where data 
allows. Where possible we have aligned other outcomes to those 
of both the Roberts et al. Cochrane review7, and also the Crown 
group core outcomes set for interventions to prevent preterm 
birth48. 
Secondary fetal/neonatal outcomes. 
1. Stillbirth
2. Respiratory Distress Syndrome
3. Moderate/severe respiratory distress syndrome
4. Birthweight (g)
5. Hypoglycaemia (blood glucose <2.5mmol/l)
6. Neonatal Unit Admission (level and duration)
7. Neonatal infection confirmed by positive culture (early 
(within first 72 hours) and late)
8. Chronic lung disease (need for continuous supplemental 
oxygen at 28 days postnatal age or 36 weeks’ 
postmenstrual age, whichever was later)
9. Apgar score less than seven at five minutes
10. Intraventricular haemorrhage (IVH) grade 3 or 4
11. Periventricular leukomalacia (PVL)
12. Retinopathy of prematurity grade 3 or 4
13. Interval between trial entry and birth
14. Length at birth (height)
15. Head circumference at birth
16. Small-for-gestational age (<3rd centile for gestational 
age by WHO 1990 birthweight standards)
17. Necrotising enterocolitis (Stage 2 or 3)
Secondary maternal outcomes. 
1. Mortality
2. Admission to intensive care unit
3. Side effects of therapy (gastrointestinal upset, glucose 
intolerance or pain/infection at injection site)
4. Postnatal depression
Sensitivity and supplementary analysis
Sensitivity and subgroup analyses will be used to explore dif-
ferences in characteristics, datasets and alternative approaches 
to data synthesis. We will analyse potential effect modifiers to 
identify any particular patient groups who derive greater ben-
efit or harm from ACS administration. We will also investi-
gate whether particular therapeutic regimens are more effective 
than others, if data are available. All analyses will be described 
according to whether they were principle, subgroup or sensitivity 
analyses and whether they were pre-planned or post hoc.
If sufficient data exists, we will perform subgroup analyses 
on the following groups for the primary outcomes:
1. Number of fetuses in utero (singleton or multiple birth)
2. Indication for administration of ACT
3. Hypertensive disorders of pregnancy (pre-eclampsia, 
gestational, chronic) vs no hypertensive disorders of 
pregnancy
4. PPROM vs no PPROM
5. Suspected fetal growth restriction (FGR) vs no FGR
6. Type of glucocorticoid (betamethasone or 
dexamethasone)
7. GA when first course of ACT given (<23 weeks, 23–28 
weeks, 28–32 weeks, 32–34 weeks, 34–36 weeks, >36 
weeks)
8. Length of time from administration of first dose of ACT 
until birth (<48 hours, 48 hours-7 days, 7–14 days, >14 
days.)
9. Diabetes mellitus (including gestational and 
pre-gestational diabetes) vs no diabetes mellitus
10. Concurrent tocolytic use vs no tocolytic use
11. Country income level (High, middle or low as defined 
by The World Bank49)
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12. Ethnicity (white vs African/Caribbean vs Asian vs 
mixed vs other)
13. Sex of baby
We will perform the following sensitivity analyses on the 
primary outcomes to evaluate the impact of trial design on the 
results:
1. High rate of loss to follow up
2. Year of birth (pre- and post- year 2000 and the era of 
modern neonatal care)
3. Trails with a high risk of bias (as measured using the 
RoB II tool45)
4. Inclusion of aggregate data where IPD not available
Statistical methods
Planned analysis
A detailed statistical analysis plan will be developed in 
discussion with a statistician when the extent of available data 
is known, before starting the analysis. The analysis will be 
performed on an intention to treat basis.
Outcome measures
For dichotomous outcomes, a log-binomial regression model 
will be performed to calculated risk ratios comparing ACT use 
with placebo/no treatment. For continuous outcomes, linear 
regression will be performed to calculate mean differences 
between treatment arms. For time-to-event outcomes, cox 
regression will be performed to calculate hazard ratios.
Unit of analysis
Pregnancy will be used as the unit of analysis for maternal and 
birth outcomes and liveborn child will be used for infant and 
childhood outcomes. Analyses will be adjusted for clustering 
(for example with Generalised Estimating Equations) in 
multiple pregnancies where possible.
One- and two-stage models
We will use one-stage models- where all IPD from all trials 
is analysed together accounting for clustering within trials. 
We will also use two-stage models where effect estimates 
are calculated for each trial individually then pooled in a 
meta-analysis.
Subgroup analysis
Subgroup analysis in one-stage meta-analysis will be performed 
by adding an interaction term between the subgrouping vari-
able and treatment allocation to the regression model. If there is 
a sign of interaction (pinteraction < 0.1), one-stage meta-analysis 
will be stratified by the subgrouping variable.
In two-stage meta-analysis, stratified analysis by the subgroup-
ing variable will be performed on the trial level and results 
will be pooled in a meta-analysis. Heterogeneity of the strati-
fied treatment effects will be assessed to determine whether any 
effect modification is present.
Relative and absolute differences
Absolute differences and number needed to treat will be 
calculated by applying risk ratios to baseline incidences.
Unavailable trials and missing data
If we are unable to obtain IPD from a given study, aggre-
gate data from the publication will be used where possible and 
be incorporated via two-stage meta-analysis.
Datasets in which any particular outcome or variable is not 
recorded will not contribute to related analyses. Where data 
are missing for some participants, a complete case analysis 
excluding these patients will be performed initially. If there 
are more substantial missing data (>10% for any covariate), 
multiple imputation will be used to impute missing variables 
within each dataset. Sensitivity analyses will be used to assess 
the impact of missingoutcome data.
Software
Analysis will be performed using the R software package.
Reporting
Results will be presented and discussed with the Co-opt group, 
with whom the interpretation of results and final report will 
be confirmed. Results will be reported in concordance with 
the PRISMA-IPD50. Plain language summaries of findings 
will be produced.
Data repository
This analysis will result in the creation of a new database of 
IPD stored securely and anonymously. This data will only be 
shared with the explicit approval of data controllers. Without 
this approval, data will be securely destroyed at the end of the 
project within the secure network. If data sharing is permitted we 
will create and anonymised data sharing repository.
Dissemination of information
We intend to publish our findings in a peer-reviewed scientific 
journal. We also intend to present any findings at relevant scien-
tific conferences. All aggregate data will be collated and shared 
upon publication and where permissions are given we will 
share all IPD.
Study status
A systematic literature search has been completed by two 
independent reviewers and we are currently in the process of 
contacting authors of all identified studies to invite them to 
collaborate.
Discussion
This IPD meta-analysis is part of a wider project by the 
Co-opt working group evaluating the use and effects of 
medications during pregnancy. All investigators of this analy-
sis are part of the Co-opt group and all results will be dis-
cussed by the group. Results will be reported in accordance 
with the PRISMA-IPD guidelines and will be used to inform 
evidence-based clinical practice.
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Data availability
Underlying data
No data are associated with this article.
Extended data
Open Science Framework: An evaluation of the benefits and harms 
of antenatal corticosteroid treatment for women at risk of imminent 
preterm birth or prior to elective Caesarean-section: an individual 
participant data meta-analysis. https://doi.org/10.17605/OSF.
IO/2TQNK44
This project contains the following extended data:
- Data outcomes.docx (List of data items to be collected)
- Search strategies.docx (Study search strategies)
Reporting guidelines
Open Science Framework: PRISMA-P checklist for ‘An evalua-
tion of the benefits and harms of antenatal corticosteroid treatment 
for women at risk of imminent preterm birth or prior to elective 
Caesarean-section: Study protocol for an individual participant 
data meta-analysis’. https://doi.org/10.17605/OSF.IO/2TQNK44
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Acknowledgements
Co_Opt collaboration:
Professor K Allergaert (KU Leuven, Belgium)
Associate Professor C Bannerman-Gyamfi (Columbia University, 
USA)
Dr Jasper Been (Erasmus MC, Netherlands)
Dr S Bhattacharya (University of Aberdeen, UK)
Associate Professor K Einarsdottir (Centre for Health Sciences, 
University of Iceland)
Dr Abigail Fraser (University of Bristol, UK)
Professor M Gissler (National Institute of Health and Welfare, 
Finland)
Professor Lani Florian (University of Edinburgh, UK)
Professor B Jacobsson (Sahlgrenska Academy, University of 
Gothenburg, Sweden)
Professor S Kuhle (Dalhousie University, Canada)
Professor B Mol (University of Adelaide, Australia)
Dr Sarah Murray (University of Edinburgh)
Professor Jane Norman (University of Bristol, UK)
Associate Professor L Pedersen (Aarhus University, Denmark)
Professor R Reynolds (University of Edinburgh, UK)
Professor R Riley (University of Keele, UK)
Dr D Roberts (Liverpool Women’s Hospital, UK)
Assistant Professor E Schuit (UMC Utrecht, the Netherlands)
Professor Aziz Sheikh (University of Edinburgh, UK)
Dr J Vogel (Maternal and Perinatal Health, WHO)
Dr Rachael Wood (University of Edinburgh, UK)
Professor J Wright (Bradford Institute for Health Research, UK)
Professor Helga Zoega (Centre for Big Data Research in Health, 
UNSW Australia)
References
1. Preterm birth. (accessed Nov 21, 2019).  
Reference Source
2. Hrabalkova L, Takahashi T, Kemp MW, et al.: Antenatal Corticosteroids for 
Fetal Lung Maturity - Too Much of a Good Thing? Curr Pharm Des. 2019; 25(5): 
593–600.  
PubMed Abstract | Publisher Full Text 
3. Kemp MW, Newnham JP, Challis JG, et al.: The clinical use of corticosteroids in 
pregnancy. Hum Reprod Update. 2016; 22(2): 240–59.  
PubMed Abstract | Publisher Full Text 
4. Vogel JP, Oladapo OT, Pileggi-Castro C, et al.: Antenatal corticosteroids for 
women at risk of imminent preterm birth in low-resource countries: the case 
for equipoise and the need for efficacy trials. BMJ Glob Health. 2017; 2(3): 
e000398.  
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al.: Antenatal Betamethasone 
for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016; 374(14): 
1311–20.  
PubMed Abstract | Publisher Full Text | Free Full Text 
6. Levels and trends in child mortality 2019 | UNICEF. (accessed Jan 28, 2020). 
Reference Source
7. Roberts D, Brown J, Medley N, et al.: Antenatal corticosteroids for accelerating 
fetal lung maturation for women at risk of preterm birth. Cochrane Database 
Syst Rev. 2017; 3: CD004454.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. Bolt RJ, van Weissenbruch MM, Lafeber HN, et al.: Glucocorticoids and lung 
development in the fetus and preterm infant. Pediatr Pulmonol. 2001; 32(1): 
76–91.  
PubMed Abstract | Publisher Full Text 
9. Liggins GC, Howie RN: A controlled trial of antepartum glucocorticoid 
treatment for prevention of the respiratory distress syndrome in premature 
infants. Pediatrics. 1972; 50(4): 515–25.  
PubMed Abstract 
10. Crowley P, Chalmers I, Keirse MJ: The effects of corticosteroid administration 
before preterm delivery: an overview of the evidence from controlled trials. Br 
J Obstet Gynaecol. 1990; 97(1): 11–25.  
PubMed Abstract | Publisher Full Text 
11. Profit J, Goldstein BA, Tamaresis J, et al.: Regional variation in antenatal 
corticosteroid use: a network-level quality improvement study. Pediatrics. 2015; 
135(2): e397–404.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 9 of 13
Wellcome Open Research 2020, 5:38 Last updated: 04 JUN 2020
12. Travers CP, Clark RH, Spitzer AR, et al.: Exposure to any antenatal 
corticosteroids and outcomes in preterm infants by gestational age: 
prospective cohort study. BMJ. 2017; 356: j1039.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13. Grzeskowiak LE, Grivell RM, Mol BW: Trends in receipt of single and repeat courses 
of antenatal corticosteroid administration among preterm and term births: A 
retrospective cohort study. Aust N Z J Obstet Gynaecol. 2017; 57(6): 643–50.  
PubMed Abstract | Publisher Full Text 
14. WHO | WHO Model Lists of Essential Medicines. WHO. 2019.  
Reference Source
15. Jonathan HG, Stoltenberg RH: UN Commission on life-saving commodities for 
women and children. 2012; (accessed Aug 7, 2019).  
Reference Source
16. WHO recommendation on antenatal corticosteroid therapy for women at risk 
of preterm birth from 24 weeks to 34 weeks of gestation | RHL. (accessed Oct 
25, 2019).  
Reference Source
17. Reynolds RM: Glucocorticoid excess and the developmental origins of 
disease: two decades of testing the hypothesis--2012 Curt Richter Award 
Winner. Psychoneuroendocrinology. 2013; 38(1): 1–11.  
PubMed Abstract | Publisher Full Text 
18. Dalziel SR, Walker NK, Parag V, et al.: Cardiovascular risk factors after 
antenatal exposure to betamethasone: 30-year follow-up of a randomised 
controlled trial. Lancet. 2005; 365(9474): 1856–62.  
PubMed Abstract | Publisher Full Text 
19. Wapner RJ, Sorokin Y, Mele L, et al.: Long-term outcomes after repeat doses of 
antenatal corticosteroids. N Engl J Med. 2007; 357(12): 1190–8.  
PubMed Abstract | Publisher Full Text 
20. Crowther CA, Doyle LW, Haslam RR, et al.: Outcomes at 2 years of age after 
repeat doses of antenatal corticosteroids. N Engl J Med. 2007; 357(12):  
1179–89.  
PubMed Abstract | Publisher Full Text 
21. Jobe AH, Goldenberg RL: Antenatal corticosteroids: an assessment of 
anticipated benefits and potential risks. Am J Obstet Gynecol. 2018; 219(1): 
62–74.  
PubMed Abstract | Publisher Full Text 
22. Sotiriadis A, Makrydimas G, Papatheodorou S, et al.: Corticosteroids for 
preventing neonatal respiratory morbidity after elective caesarean section at 
term. Cochrane Database Syst Rev. 2009; (4): CD006614.  
PubMed Abstract | Publisher Full Text 
23. Crowther CA, McKinlay CJ, Middleton P, et al.: Repeat doses of prenatal 
corticosteroids for women at risk of preterm birth for improving neonatal 
health outcomes. Cochrane Database Syst Rev. 2015; (7): CD003935.  
PubMed Abstract | Publisher Full Text 
24. Crowther CA, Middleton PF, Voysey M, et al.: Effects of repeat prenatal 
corticosteroids given to women at risk of preterm birth: An individual 
participant data meta-analysis. PLoS Med. 2019; 16(4): e1002771.  
PubMed Abstract | Publisher Full Text | Free Full Text 
25. Saccone G, Berghella V: Antenatal corticosteroids for maturity of term or near 
term fetuses: systematic review and meta-analysis of randomized controlled 
trials. BMJ. 2016; 355: i5044.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Althabe F, Thorsten V, Klein K, et al.: The Antenatal Corticosteroids Trial (ACT)’s 
explanations for neonatal mortality - a secondary analysis. Reprod Health. 
2016; 13(1): 62.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Althabe F, Belizan JM, McClure EM, et al.: A Population-Based, Multifaceted 
Strategy to Implement Antenatal Corticosteroid Treatment Versus Standard 
Care for the Reduction of Neonatal Mortality Due to Preterm Birth in Low-
Income and Middle-Income Countries: The ACT Cluster Randomized Trial. 
Obstet Gynecol Surv. 2015; 70(6): 379–381.  
Publisher Full Text 
28. Kolås T, Saugstad OD, Daltveit AK, et al.: Planned cesarean versus planned 
vaginal delivery at term: Comparison of newborn infant outcomes. Am J Obstet 
Gynecol. 2006; 195(6): 1538–43.  
PubMed Abstract | Publisher Full Text 
29. Stutchfield P, Whitaker R, Russell I, et al.: Antenatal betamethasone and 
incidence of neonatal respiratory distress after elective caesarean section: 
pragmatic randomised trial. BMJ. 2005; 331(7518): 662.  
PubMed Abstract | Publisher Full Text | Free Full Text 
30. World Health Organization: WHO Recommendations on Interventions to 
Improve Preterm Birth Outcomes. Geneva, 2015.  
Reference Source
31. Razaz N, Skoll A, Fahey J, et al.: Trends in Optimal, Suboptimal, and 
Questionably Appropriate Receipt of Antenatal Corticosteroid Prophylaxis. 
Obstet Gynecol. 2015; 125(2): 288–96.  
PubMed Abstract | Publisher Full Text 
32. FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine: Good 
clinical practice advice: Prediction of preterm labor and preterm premature 
rupture of membranes. Int J Gynecol Obstet. 2019; 144(3): 340–6.  
PubMed Abstract | Publisher Full Text 
33. FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine: Good 
clinical practice advice: Prediction of preterm labor and preterm premature 
rupture of membranes. Int J Gynecol Obstet. 2019; 144(3): 340–6.  
PubMed Abstract | Publisher Full Text 
34. Kenyon SL, Taylor DJ, Tarnow-Mordi W, et al.: Broad-spectrum antibiotics for 
preterm, prelabour rupture of fetal membranes: the ORACLE I randomised 
trial. ORACLE Collaborative Group. Lancet. 2001; 357(9261): 979–88.  
PubMed Abstract | Publisher Full Text 
35. Whitsett JA, Matsuzaki Y: Transcriptional Regulation of Perinatal Lung 
Maturation. Pediatr Clin North Am. 2006; 53(5): 873–87.  
PubMed Abstract | Publisher Full Text 
36. Ontela V, Dorairajan G, Bhat VB, et al.: Effect of Antenatal Steroids on 
Respiratory Morbidity of Late Preterm Newborns: A Randomized Controlled 
Trial. J Trop Pediatr. 2018; 64(6): 531–8.  
PubMed Abstract | Publisher Full Text 
37. Nada AM, Shafeek MM, El Maraghy MA, et al.: Antenatal corticosteroid 
administration before elective caesarean section at term to prevent neonatal 
respiratory morbidity: A randomized controlled trial. Eur J Obstet Gynecol 
Reprod Biol. 2016; 199: 88–91.  
PubMed Abstract | Publisher Full Text 
38. Mirzamoradi M, Hasani Nejhad F, Jamali R, et al.: Evaluation of the effect of 
antenatal betamethasone on neonatal respiratory morbidities in late preterm 
deliveries (34–37 weeks). J Matern Fetal Neonatal Med. 2019; 1–8.  
PubMed Abstract | Publisher Full Text 
39. Delibas IB, Ingec M, Yapca OE: Does antenatal betamethasone have negative 
effects on fetal activities and hemodynamics in cases of preeclampsia without 
severe features? A prospective, placebo-controlled, randomized study.  
J Matern Neonatal Med. 2017; 30(22): 2671–8.  
PubMed Abstract | Publisher Full Text 
40. Riley RD, Lambert PC, Abo-Zaid G: Meta-analysis of individual participant data: 
Rationale, conduct, and reporting. BMJ. 2010; 340: c221.  
PubMed Abstract | Publisher Full Text 
41. Lyman GH, Kuderer NM: The strengths and limitations of meta-analyses based 
on aggregate data. BMC Med Res Methodol. 2005; 5: 14.  
PubMed Abstract | Publisher Full Text | Free Full Text 
42. Stewart LA, Tierney JF: TO IPD OR NOT TO IPD? Advantages and 
Disadvantages of Systematic Reviews Using Individual Patient Data. Eval 
Health Prof. 2002; 25(1): 76–97. 
PubMed Abstract | Publisher Full Text 
43. Liberati A, Altman DG, Tetzlaff J, et al.: The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. PLoS Med. 2009; 6(7): e1000100. 
PubMed Abstract | Publisher Full Text | Free Full Text 
44.  Wastnedge E: An evaluation of the benefits and harms of antenatal 
corticosteroid treatment for women at risk of imminent preterm birth or 
prior to elective Caesarean-section: an individual participant data meta-
analysis.2020.  
Publisher Full Text
45. Risk of bias tools - RoB 2 tool. (accessed Nov 20, 2019).  
Reference Source
46. WHO | Maternal and perinatal health. (accessed Nov 22, 2019).  
Reference Source
47. Overview | Hypertension in adults: diagnosis and management | Guidance | 
NICE. (accessed Jan 6, 2020).  
Reference Source
48. van `t Hooft J, Duffy JMN, Daly M, et al.: A Core Outcome Set for Evaluation of 
Interventions to Prevent Preterm Birth. Obstet Gynecol. 2016; 127(1): 49–58. 
PubMed Abstract | Publisher Full Text 
49. WDI - Classifying countries by income. (accessed Nov 20, 2019).  
Reference Source
50. Stewart LA, Clarke M, Rovers M, et al.: Preferred Reporting Items for Systematic 
Review and Meta-Analyses of individual participant data: the PRISMA-IPD 
Statement. JAMA. 2015; 313(16): 1657–65.  
PubMed Abstract | Publisher Full Text 
Page 10 of 13
Wellcome Open Research 2020, 5:38 Last updated: 04 JUN 2020
 Open Peer Review
  Current Peer Review Status:
Version 1
 02 June 2020Reviewer Report
https://doi.org/10.21956/wellcomeopenres.17160.r38530
© 2020 Carlo W. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Waldemar A. Carlo
Department of Pediatrics, The University of Alabama at Birmingham, Birmingham, AL, USA
Summary 
This manuscript is the study protocol for a planned individual participant meta-analysis (IPD-MA) of
antenatal corticosteroid treatment for women at risk of imminent preterm birth or prior to elective
Caesarean section (CS). Antenatal corticosteroid therapy (ACT) is one of the most beneficial therapies for
threatened preterm labor and possibly other perinatal causes but many infants who may not benefit much
are exposed and may have side effects. There are abundant data from RCTs. An IPD-MA is an ideal way
to sort out the subgroups of mothers whose infants may benefit or not from exposure to ACT.
 
The protocol is well designed and addresses several controversies in ACT including ACT given at >34
weeks gestation, ACT given prior to planned Caesarean-section, ACT given when the time from the
previous ACT has been >7 days, and ACT given to those who deliver at term 
 
Plain language summary
It is stated: “Antenatal corticosteroid treatment (ACT) has long been used to help reduce respiratory
problems and neonatal death and is a cornerstone of treatment when preterm birth (defined as birth at
<37 weeks gestation) is planned or expected, or when Caesarean-section at any gestation, is planned.” I
would not consider that ACT “has long been used” or is “a cornerstone of treatment” for preterm labor at
34 to 36 weeks of for CS. These indications are more recent. The benefits of ACT in these infants are
generally less consequential (no reduction in perinatal or neonatal deaths) and more marginal for RDS.
Furthermore, harms have been reported, and there is more controversy on the use of ACT in these
populations.
 
 Introduction
This is an important IPD-MA as subgroups analyses are needed to be able to ascertain better the benefits
and harms of ACT for specific patient subgroups and to better individualize patient care.
 
Several subgroup analyses are planned. The four subgroups of studies when ACT is given >34 weeks
gestation, when ACT is given prior to planned Caesarean-section, when ACT is given when the time from
a previous ACT is >7 days, and when ACT given to those who deliver at term are important and
controversial indications that an IPD-MA can address well.
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 controversial indications that an IPD-MA can address well.
 
A subgroup IPD-MA that would be so important but is not considered would be by gestational age
between 26 and 34 weeks of birth. It would be ideal to use an IPD-MA to determine the association of
ACT and serious outcomes such as death at each week of gestation. The observational study by Travers 
suggest that there is more than a 10-fold differences between in neonatal mortality in this wide rangeet al. 
of gestational ages. Important benefits may not occur at gestational ages close to 34 weeks. Furthermore,
these data are not by gestational age of treatment and are prone to bias as they are from an observational
study. The suggestion is that this subgroup be added to the IPD-MA planned or a subsequent IPD-MA is
performed on the subject. This is something I suspect the Co-opt working group has considered.
 
Methods and Design
The study design is appropriate for the research questions. The authors use the PRISMA reporting
guidelines to assure that the study will meet these specific guidelines.
 
It is not clear if the subgroup analyses of the studies of ACT at >34 weeks will include an analysis at each
week of gestation. Outcomes differ markedly at 34, 35, and 36 weeks, and this will be better addressed in
an IPD-MA than in the individual RCTs.
 
For the planned analyses, GA when first course of ACT given (<23 weeks, 23–28 weeks, 28–32 weeks,
32–34 weeks, 34–36 weeks, >36 weeks), it would be preferable to analyze the data by each week of
gestation. If this is not possible, smoothing could be used by using three GAs at a time and moving over a
week at a time.
 
There is evidence that benefits may occur at much less than 48 hours post ACT. The planned subgroup
analyses are for: length of time from administration of first dose of ACT until birth (<48 hours, 48 hours-7
days, 7–14 days, >14 days). It would be ideal to also use <24 hours as some emerging data indicate that
most of the benefits can occur when birth is less than 24 hours after ACT.
Is the rationale for, and objectives of, the study clearly described?
Yes
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: I was the PI of the main trial and of the grant that funded the NEOPROM IPD-MA.
Established current guidelines, initially published in 1995, recommend antenatal corticosteroids for
mothers with preterm labor from 24 to 34 weeks' gestational age, but not before 24 weeks due to lack of
data. However, many infants born before 24 weeks' gestation are provided intensive care.
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expertise to confirm that it is of an acceptable scientific standard.
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   Martijn A. Oudijk
Department of Obstetrics and Gynaecology, Amsterdam UMC, University of Amsterdam, Amsterdam,
The Netherlands
This protocol for an IPD meta-analysis on the use of antenatal corticosteroids for threatened preterm birth
of women planned for C section is set up well, and expected to provide the obstetric community with
important answers regarding the effects of ACT. Especially the long term FU section is of the utmost
importance.
The group is expected to deliver this IPDMA, as they are all experts within this field, with excellent track
records.
Is the rationale for, and objectives of, the study clearly described?
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Is the study design appropriate for the research question?
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Are sufficient details of the methods provided to allow replication by others?
Yes
Are the datasets clearly presented in a useable and accessible format?
Yes
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